updat highlight return top-line growth
upbeat updat highlight busi progress deliv impress
financi result includ adj -ep vs consensu
estim driven revenu easili outpac
consensu estim repres consecut year
revenu encourag prospect top-line growth base
growth y/i expect midpoint guidanc ep guidanc
conserv expect growth y/i mid-point
adj -ep consensu impli oper margin compress
optimist outlook especi ahead key clinic trial readout
updat model reflect actual guidanc detail insid
forecast revenu adj -ep within upper
half guidanc oper margin estim declin vs
consist manag commentari around invest
infrastructur expect top-line grow steadili
oper margin expans resum reach exhibit
amidst price headwind expect similar deliv
substanti volum growth global ex-u geograph expans
especi recent launch repatha even blincyto bgne collabor
open larg opportun oncolog china astella jv revert
wholly-own subsidiari japan anticip sale
growth asia-pacif within ten year
pipelin catalyst unlock signific valu kras-
inhibitor trial nsclc complet enrol initi data expect
also await combin data anti-bcma bite mm
initi clinic data expect read addit readout
includ tezepelumab severe/uncontrolled-asthma omecamtiv mercarbil
cv-outcom data otezla mild/moderate-psoriasi data
biosimilar increasingli becom growth driver annual
note strong us sale kanjinti mvasi receiv
us approv biosimilar remicad submit bla biosimilar rituxan
current domin market share ex-u market
indic biosimilar could becom multibillion-dollar opportun
capit alloc remain focu return sharehold
dividend buyback rais quarterli dividend
anticip buyback expect continu
invest prudent bd opportun cash pt tweak
year price histori
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel stabl
next year margin expand manag
track record financi disciplin top line believ
posit maintain long-term revenu stabil
matur product declin new product continu grow
pipelin deliv steadi flow new product
offer dividend yield believ provid valuat
updat data kra inhibitor major
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top-lin essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
exhibit actual vs oppenheim consensu estim
exhibit revenu forecast increas steadili
incom growth oppenheimerest vs oppenheim consensu estimate actual vs consensu actual growth oppenheim estimate vs oppenheim consensusest vs consensu updat midpoint total non-gaap cog margin rate incom ep growth oppenheimerest vs oppenheim consensu estimate actual vs consensu actual growth oppenheim estimate vs oppenheim consensusest vs consensu revenu estim pipelinehpt secondari ckdprimari caredenosumaboncologyauto-immunegrowth factorsoth inc
exhibit note histor give low guidanc call
exhibit dcf valuat support pt
call guidanc call guidanc rangetypey non-gaap discount analysi except per-shar data revenu incom chang work work capit valu growth valu oppenheim estim compani reportsequ valu per sharetermin valu growth rate outperform
net incom equiti invest bgne
stock price compani mention report
